While Foundayo is well-tolerated by most people, some should not take the drug, including: Those with a history or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or other thyroid cancers should not take Foundayo
Combining mono- and/or dual-agonists to achieve triple agonism may allow for personalisation of treatment, aiming to find the optimal balance of receptor agonism for a specific individual
Clauss, M., Grard, P., Mosca, A
The study demonstrated that once-weekly subcutaneous cagrilintide alone resulted in significant and sustained body weight reductions in individuals with overweight or obesity
Use morning and night
1j and Supplementary Data 1)